Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NASOX plus camrelizumab as neoadjuvant/conversion therapy in pancreatic cancer
ChiCTR2500113349Phase 4Not yet recruiting
- Sponsor
- The First People's Hospital of Yunnan Province
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nanoliposomal irinotecan, oxaliplatin, tegafur and camrelizumab in pancreatic cancer (PC), sponsored by The First People's Hospital of Yunnan Province. Primary endpoint: Objective response rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecanoxaliplatintegafurcamrelizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500113349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113349.